BULL Pharmachem
BULL Pharmachem
Kalbadevi, Mumbai, Maharashtra
GST No. 27AKFPJ6383E1Z2
TrustSEAL Verified
Call 0804897311982% Response Rate
SEND EMAIL
 

Nephrology Medicines

Our range of products include rapacan 1mg tablets.

Rapacan 1mg Tablets

Rapacan 1mg Tablets
  • Rapacan 1mg Tablets
  • Rapacan 1mg Tablets
  • Rapacan 1mg Tablets
  • Rapacan 1mg Tablets
  • Rapacan 1mg Tablets
  • Rapacan 1mg Tablets
  • Rapacan 1mg Tablets
Get Best Quote
Approx. Price: Rs 650 / StripeGet Latest Price

Product Details:

Strength1 mg
Prescription/Non prescriptionPrescription
Packaging Size10 x 10
BrandRapacan
Pack Type1 strip of 10 tablets
CompositionSirolimus 1 mg
DoseAs per physician
ManufacturerBiocon
TreatmentImmunosuppresive Drug
Side EffectAs per physician directions

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mechanistic target of rapamycin kinase (mTOR) inhibitor[2] that inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2).

It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972, from samples of Streptomyces hygroscopicus found on Easter Island. The compound was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the U.S. Food and Drug Administration (FDA) in September 1999

 

Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment of lymphangioleiomyomatosis (LAM).

Sirolimus (Fyarro), as protein-bound particles, is indicated for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

The most common adverse reactions (≥30% occurrence, leading to a 5% treatment discontinuation rate) observed with sirolimus in clinical studies of organ rejection prophylaxis in individuals with kidney transplants include: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, pain, constipation, hypertriglyceridemia, hypertension, increased creatinine, fever, urinary tract infection, anemia, arthralgia, and thrombocytopenia.

The most common adverse reactions (≥20% occurrence, leading to an 11% treatment discontinuation rate) observed with sirolimus in clinical studies for the treatment of lymphangioleiomyomatosis are: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, chest pain, stomatitis, nasopharyngitis, acne, upper respiratory tract infection, dizziness, and myalgia.[

 

Request
Callback


Additional Information:

  • Item Code: Rapacan
  • Production Capacity: 1000000
  • Delivery Time: 7-10 days
  • Packaging Details: 10 strips x 10 tablets
Yes! I am Interested
X

Explore More Products

View All Products




Reach Us
Rakshit Jain (Sales & Marketing Manager)
BULL Pharmachem
No. 64C, Dhan Sadan Co Operative Housing Society, 2nd Floor
Kalbadevi, Mumbai - 400002, Maharashtra, India


Call Us


Send E-mail